Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study

BACKGROUND: Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents. The aim of this retrospective study was to assess the efficacy and safety of pembrolizumab plus lenvatinib plus hepatic arterial infu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Song, Xu, Bo, Wu, Zhiqiang, Wang, Pengfei, Yu, Weiguang, Liu, Zhiyong, Huang, Xiaoyong, Wu, Yanqing, Li, Tengfei, Guo, Wenbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527794/
https://www.ncbi.nlm.nih.gov/pubmed/34670506
http://dx.doi.org/10.1186/s12885-021-08858-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527794/
https://www.ncbi.nlm.nih.gov/pubmed/34670506
http://dx.doi.org/10.1186/s12885-021-08858-6

Ejemplares similares